Navigation Links
CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal
Date:2/20/2009

Dear Mr. Nogimori: The CV Therapeutics board of directors is committed to enhancing value for our stockholders. The board, with the assistance of its financial and legal advisors, has carefully considered your proposal to acquire our company in the context of our strategic plans and the best interests of our stockholders. We concluded that your proposal significantly undervalues CV Therapeutics and its potential growth opportunities and we decline to accept it. CV Therapeutics has a strategic plan in place which we believe will enhance shareholder value. Moreover, as we stated in our press release, we have always been, and remain, receptive to opportunities to further enhance shareholder value. Sincerely, Dr. Louis Lange Chairman and Chief Executive Officer

As previously announced, CV Therapeutics received a letter dated November 13, 2008 from Astellas setting forth an unsolicited proposal by Astellas to acquire the company at a price of $16.00 per share, subject to due diligence, Astellas board approval and other conditions. On November 21, 2008, after careful deliberation, with the assistance of its financial and legal advisors, the CV Therapeutics board of directors concluded that the Astellas proposal was not in the best interests of CV Therapeutics and its stockholders. Dr. Louis Lange, chairman and chief executive officer of CV Therapeutics, sent a letter dated November 21, 2008 to that effect to Astellas on behalf of the board of directors of CV Therapeutics.

Barclays Capital and Goldman Sachs are serving as financial advisors, and Latham & Watkins LLP is serving as legal counsel, to CV Therapeutics.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
2. Sopherion Therapeutics Secures $55 Million in Series C Funding
3. Amicus Therapeutics Announces Change to Board of Directors
4. Opsona Therapeutics Closes EUR18M Funding
5. Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
6. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
7. United Therapeutics to Announce 2008 Fourth Quarter and Annual Financial Results Before Market Open on Tuesday, February 17, 2009
8. Northwest Biotherapeutics Secures $700,000 Equity Financing
9. iCo Therapeutics Closes $1.3 Million Private Placement
10. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... one of the interesting and challenging endeavors as ... renders highly impervious properties to the foreign substances. ... as possibility of self medication and minimal use ... low molecular weight drugs and provides specific targeting ...
(Date:8/22/2014)... 2014 The AMA is pleased to ... in Alaska that Alaska Governor Sean Parnell has signed ... defining public use of Unmanned Aircraft Systems and the ... Bill 255states that it is, “An Act relating to ... an unmanned aircraft system.” It defines State of Alaska ...
(Date:8/21/2014)... Aug. 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... first in class collagenase-based products marketed as XIAFLEX ... the U.S. and XIAPEX ® in the ... a randomized, double-blind Phase 2a study of CCH ... fibrosclerotic panniculopathy. The results showed that all three ...
(Date:8/21/2014)... 21, 2014 2014 Deep ... is a professional and in-depth research report ... provides basic Seaweed Fertilizer information, including Seaweed ... structure as well as industry overview. This ... domestic market as well as global industry ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
... ... -, SOUTH ... of a recent Harris,Interactive(R) survey, showing that an overwhelming majority of Tracleer,patients ... their knowledge of pulmonary arterial hypertension (PAH) and,Tracleer have improved due to ...
... /PRNewswire-FirstCall/ - Helix BioPharma Corp.,(TSX, FSE: "HBP") today announced financial results ... HIGHLIGHTS ---------- - Subsequent to the ... CDN$16.9 million private placement of common shares, subject to ... with Dr. Donald H. Segal remaining the ...
... 17 IRIDEX,Corporation (Nasdaq: IRIX ) today ... Company as Chief Financial Officer effective January 2, ... Officer and Vice President,of Finance for NextHop Technologies, ... as Vice President of Finance and Chief,Financial Officer ...
Cached Biology Technology:Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 2Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 3Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 4Helix BioPharma announces Q1 2008 financial results 2Helix BioPharma announces Q1 2008 financial results 3Helix BioPharma announces Q1 2008 financial results 4Helix BioPharma announces Q1 2008 financial results 5Helix BioPharma announces Q1 2008 financial results 6Helix BioPharma announces Q1 2008 financial results 7Helix BioPharma announces Q1 2008 financial results 8Helix BioPharma announces Q1 2008 financial results 9Helix BioPharma announces Q1 2008 financial results 10Helix BioPharma announces Q1 2008 financial results 11IRIDEX Announces James Mackaness Will Be Chief Financial Officer 2
(Date:8/21/2014)... to ignore, but they are the ultimate source of ... are increasingly dependent on algae, too, to suck up ... to the bottom of the ocean. Now, by using ... have evidence showing that viruses infecting those algae are ... when all else stays essentially the same, and this ...
(Date:8/21/2014)... MELBOURNE, Fla. , Aug. 21, 2014 ...  announced that it has agreed to a ... Orlando,s fastest growing Certified ... make  Gabriel Health Institute  an exclusive member ... a result, Binary Biometrics will improve its ...
(Date:8/21/2014)... from Beth Israel Deaconess Medical Center (BIDMC ) are ... Influential Scientific Minds 2014," a comprehensive list ... resource for science metrics and research performance analysis. ... influential "are performing and publishing work that their peers ... according to a Thomson Reuters statement. Researchers were identified ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... spiders, and other venomous creatures, the "business end," or active ... of a protein that is most likely to undergo rapid ... Gurion University in Israel. Understanding these evolutionary forces can help ... and may also aid in the design of novel synthetic ...
... world, allocating limited health care resources as effectively and ... address that need, systems engineers at the Georgia Institute ... nations improve supply chain decisions related to the distribution ... are also forecasting what health care services would be ...
... Extensive ongoing research on biotic invasions around the world ... research in the United States shows how using improved ... plant species changes the understanding of patterns of species ... was published in the open access journal ...
Cached Biology News:Molding the business end of neurotoxins 2Engineers improve allocation of limited health care resources in resource-poor nations 2Engineers improve allocation of limited health care resources in resource-poor nations 3Human population the primary factor in exotic plant invasions in the United States 2
Request Info...
R26.4C...
... Specifications(L x W x H): 17 ... 5 5/16"18.7 lbsCapacity: 12 slidesTime: Programmable 0 ... Automated denaturation and hybridization steps 40 user ... only, and Fixed temperature) Rapid temperature ramp-up ...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Biology Products: